Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.
Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) for metastatic melanoma has shown objective response rates as high as 72%. The successful application of this therapy requires the selection of unique tumor-reactive lymphocyte cultures for each patient. This is a technically and logistically difficult undertaking, and patients who do not have tumor-reactive TIL are not considered eligible for treatment. To simplify the methods of TIL generation and extend TIL-based immunotherapy to additional patients, methods were developed to use unselected, minimally cultured ("young") TIL. Young TIL cultures contain a variable number of CD8(+), CD4(+), and CD3(-)CD56(+) natural killer cells. In this study we retrospectively investigated a role for these subsets in the clinical outcome of patients treated with TIL derived from selected microcultures. This analysis demonstrated a suggestive but nonsignificant association between the number of CD8(+) cells administered and tumor regression. We therefore investigated the feasibility of selecting CD8(+) cells from young TIL cultures for ACT therapy. The available methods for clinical scale CD8(+) enrichment proved inadequate for TIL, so an optimized CD8(+) enrichment method was developed and is reported here. We observed that CD8 (+)enrichment of some TIL cultures revealed in vitro tumor recognition that was not evident in bulk culture, and an improved in vitro recognition of tumor in other TIL cultures. In addition, the enriched CD8(+) young TIL expanded more reliably and predictably in rapid expansions than the bulk TIL. Thus, optimized CD8(+) selection combines the benefits of antigen-selected TIL and young TIL for generating lymphocyte cultures for ACT, and should be evaluated in cell transfer therapy protocols.
Prieto
Peter A
PA
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1201, USA. prietop@mail.nih.gov
Durflinger
Katherine H
KH
Wunderlich
John R
JR
Rosenberg
Steven A
SA
Dudley
Mark E
ME
D000951:Antigens, Neoplasm / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism* / Q000473:pathology / Q000637:transplantation; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005434:Flow Cytometry; D015789:HLA-A2 Antigen / Q000378:metabolism; D006801:Humans; D018189:Immunomagnetic Separation; D016219:Immunotherapy, Adoptive; D007371:Interferon-gamma / Q000378:metabolism; D007519:Isoantigens / Q000276:immunology; D008213:Lymphocyte Activation; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000378:metabolism* / Q000473:pathology / Q000637:transplantation; D008545:Melanoma
D000951:Antigens, Neoplasm; D015789:HLA-A2 Antigen; C531098:HNA-4A antigen; D007519:Isoantigens; D007371:Interferon-gamma
J Immunol Methods. 1990 Apr 17;128(2):189-201
1691237
Science. 2002 Oct 25;298(5594):850-4
12242449
Gastroenterology. 2009 Oct;137(4):1270-9
19577568
J Immunother. 2005 Jul-Aug;28(4):403-11
16000960
J Immunother. 2003 Jul-Aug;26(4):332-42
12843795
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7
12826605
Cancer Treat Rev. 2008 Apr;34(2):145-56
18077098
Clin Cancer Res. 2008 Aug 15;14(16):5166-72
18698034
Clin Cancer Res. 2008 Sep 1;14(17):5610-8
18765555
J Immunother. 2009 May;32(4):415-23
19342963
J Immunol. 2005 Oct 1;175(7):4797-805
16177129
Mol Syst Biol. 2009;5:265
19401677
Cancer Immunol Immunother. 2008 May;57(5):623-34
17899077
J Immunol. 2006 Nov 1;177(9):6527-39
17056585
J Immunother. 2007 May-Jun;30(4):438-47
17457218
J Immunother. 2008 Oct;31(8):742-51
18779745
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73
12427970
Semin Oncol. 2007 Dec;34(6):532-45
18083377
Nat Med. 2004 Sep;10(9):942-9
15322536
Blood. 2006 Nov 1;108(9):2942-9
16835376
Eur J Cancer. 2009 Aug;45(12):2123-31
19398324
Blood. 2008 Dec 15;112(13):4953-60
18820132
Blood. 2008 Jul 15;112(2):362-73
18354038
Blood Cells Mol Dis. 2008 Jan-Feb;40(1):63-7
17869548
Curr Opin Immunol. 2009 Apr;21(2):233-40
19304471
Annu Rev Immunol. 2009;27:485-517
19132915
Hum Gene Ther. 2005 Apr;16(4):457-72
15871677
Cancer Immunol Immunother. 2009 May;58(5):823-30
19198837
J Immunother. 2002 May-Jun;25(3):243-51
12000866
J Immunol. 2006 Nov 1;177(9):6548-59
17056587
J Clin Oncol. 2006 Nov 1;24(31):5060-9
17075125
Science. 2006 Oct 6;314(5796):126-9
16946036
Br J Haematol. 2006 Jul;134(1):64-76
16803570
Blood. 1998 Apr 15;91(8):2925-34
9531603
J Clin Oncol. 2008 Nov 10;26(32):5233-9
18809613
J Immunother. 2001 Jul-Aug;24(4):363-73
11565838
J Immunol. 2005 Mar 1;174(5):2591-601
15728465
N Engl J Med. 2008 Jun 19;358(25):2698-703
18565862